Dorton Katina 4

What Happened

• Katina Dorton, a director of Prelude Therapeutics (PRLD), received a grant of 38,000 derivative shares (an option award) on 2026-06-09. The filing reports an acquisition at $0.00 for a total reported value of $0 — this reflects a grant/award, not an open-market purchase or sale.

Key Details

• Transaction date and type: 2026-06-09 — Grant/Award of derivative securities (Form 4 code A).
• Price reported: $0.00 per share; total reported value $0 (grant/option award).
• Shares owned after transaction: not specified in the filing.
• Vesting/conditions (footnote F1): the option award will fully vest upon the earlier of (a) the issuer's next annual stockholder meeting or (b) the one-year anniversary of the grant date, provided the reporting person continues service on each vesting date.
• Filing timeliness: Reported on 2026-06-10 for the 2026-06-09 grant — appears to be filed promptly.

Context

• This was a compensation award to a director (an option grant), not an immediate purchase or sale. Derivative awards like this typically convert into shares only after vesting and any required exercise; they do not necessarily indicate an immediate market position change. Such grants are common for board compensation and should be interpreted as part of routine insider remuneration rather than a direct bullish or bearish trade.